Atıf İçin Kopyala
Yeral M., Aytan P., Gungor B., Boga C., ÜNAL A., Koc Y., ...Daha Fazla
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.20, sa.10, ss.652-660, 2020 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
20
Sayı:
10
-
Basım Tarihi:
2020
-
Doi Numarası:
10.1016/j.clml.2020.05.009
-
Dergi Adı:
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
-
Sayfa Sayıları:
ss.652-660
-
Anahtar Kelimeler:
Autologous transplantation, Conditioning, Lymphoma, Outcome, Stem cell, HIGH-DOSE CHEMOTHERAPY, BONE-MARROW-TRANSPLANTATION, SEQUENTIAL CHEMOTHERAPY, RESPONSE CRITERIA, MITOXANTRONE, BLOOD, THERAPY, CARMUSTINE, DISEASE
-
Erciyes Üniversitesi Adresli:
Evet
Özet
In this multicenter retrospective study, we compared the efficacy and toxicity of BEAM (BCNU, etoposide, cytarabine, and melphalan) and MITO/MEL (mitoxantrone, melphalan) preparation regimens. The 3-year expected overall survival for the MIT/MEL and BEAM were 86.1% and 91.3%, respectively. The MITO/MEL seems to be as effective as the BEAM but has better tolerability in terms of pulmonary toxicity and may be used as an alternative option.